Literature DB >> 16004592

TGF-beta inhibitors for the treatment of cancer.

Michael Lahn1, Susanne Kloeker, Brandi S Berry.   

Abstract

Advances in understanding the role of transforming growth factor (TGF)-beta in tumorigenesis have led to the development of TGF-beta inhibitors for cancer treatment. Three platforms of TGF-beta inhibitors have evolved: antisense oligonucleotides, monoclonal antibodies and small molecules. In this review, the current stage of development of each known TGF-beta inhibitor will be discussed. As part of the risk/benefit assessment of TGF-beta inhibitors, the known effects of TGF-beta deficiency in mice, non-clinical toxicology studies with TGF-beta inhibitors in rats, and the clinical studies with monoclonal antibodies against TGF-beta will be summarised.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16004592     DOI： 10.1517/13543784.14.6.629

Source DB:  PubMed          Journal:  Expert Opin Investig Drugs        ISSN： 1354-3784            Impact factor:   6.206


  23 in total

1.  A local paracrine and endocrine network involving TGFβ, Cox-2, ROS, and estrogen receptor β influences reactive stromal cell regulation of prostate cancer cell motility.

Authors:  Melanie J Grubisha; M E Cifuentes; Stephen R Hammes; Donald B Defranco
Journal:  Mol Endocrinol       Date:  2012-05-16

2.  In vitro models of pancreatic cancer for translational oncology research.

Authors:  Georg Feldmann; Sherri Rauenzahn; Anirban Maitra
Journal:  Expert Opin Drug Discov       Date:  2009-04-01       Impact factor: 6.098

3.  Chemotherapeutic Targeting of the Transforming Growth Factor-β Pathway in Breast Cancers.

Authors:  Yong-Hun Lee; William P Schiemann
Journal:  Breast Cancer Manag       Date:  2014

Review 4.  [Oligonucleotide therapeutics - an emerging novel class of compounds].

Authors:  Volker Wacheck
Journal:  Wien Med Wochenschr       Date:  2006-09

Review 5.  Targeting the transforming growth factor-beta signaling pathway in human cancer.

Authors:  Nagathihalli S Nagaraj; Pran K Datta
Journal:  Expert Opin Investig Drugs       Date:  2010-01       Impact factor: 6.206

6.  Radiotherapy suppresses angiogenesis in mice through TGF-betaRI/ALK5-dependent inhibition of endothelial cell sprouting.

Authors:  Natsuko Imaizumi; Yan Monnier; Monika Hegi; René-Olivier Mirimanoff; Curzio Rüegg
Journal:  PLoS One       Date:  2010-06-11       Impact factor: 3.240

7.  A phase 1 study of anti-TGFβ receptor type-II monoclonal antibody LY3022859 in patients with advanced solid tumors.

Authors:  Anthony W Tolcher; Jordan D Berlin; Jan Cosaert; John Kauh; Emily Chan; Sarina A Piha-Paul; Alex Amaya; Shande Tang; Kyla Driscoll; Richard Kimbung; S R Prasad Kambhampati; Ivelina Gueorguieva; David S Hong
Journal:  Cancer Chemother Pharmacol       Date:  2017-03-09       Impact factor: 3.333

8.  Tissue stretch decreases soluble TGF-beta1 and type-1 procollagen in mouse subcutaneous connective tissue: evidence from ex vivo and in vivo models.

Authors:  Nicole A Bouffard; Kenneth R Cutroneo; Gary J Badger; Sheryl L White; Thomas R Buttolph; H Paul Ehrlich; Debbie Stevens-Tuttle; Helene M Langevin
Journal:  J Cell Physiol       Date:  2008-02       Impact factor: 6.384

9.  Id2, Id3 and Id4 overcome a Smad7-mediated block in tumorigenesis, generating TGF-β-independent melanoma.

Authors:  Kyle A DiVito; Cynthia M Simbulan-Rosenthal; You-Shin Chen; Valerie A Trabosh; Dean S Rosenthal
Journal:  Carcinogenesis       Date:  2013-12-16       Impact factor: 4.944

10.  An oncogenomics-based in vivo RNAi screen identifies tumor suppressors in liver cancer.

Authors:  Lars Zender; Wen Xue; Johannes Zuber; Camile P Semighini; Alexander Krasnitz; Beicong Ma; Peggy Zender; Stefan Kubicka; John M Luk; Peter Schirmacher; W Richard McCombie; Michael Wigler; James Hicks; Gregory J Hannon; Scott Powers; Scott W Lowe
Journal:  Cell       Date:  2008-11-13       Impact factor: 41.582
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.